Diamorphine

Key Takeaways

• Diamorphine is a powerful opioid used primarily for severe cancer pain and palliative care.
• It is commonly administered via subcutaneous infusion, injection, or syringe driver in hospice and hospital settings.
• Careful dose titration and clinical monitoring are essential to balance pain relief with safety.
• It remains a preferred option in palliative oncology due to its high solubility and potency compared to other opioids.
• Use should always be guided and supervised by a qualified healthcare professional.

What Is Diamorphine Used for in Cancer Pain and Palliative Care

Diamorphine, also known as heroin in non-medical contexts, is a diacetyl derivative of morphine that provides rapid and effective analgesia for patients experiencing severe pain. In oncology, it is used when other analgesics are insufficient to control cancer-related suffering. The World Health Organization (WHO) recognizes strong opioids as essential medicines for moderate-to-severe cancer pain, and diamorphine fulfills this role in countries where it is licensed, particularly the United Kingdom.

In palliative care, diamorphine is valued not only for pain management but also for relieving breathlessness and distress in the final stages of life. Its clinical benefits extend to reducing anxiety and discomfort associated with terminal illness, allowing patients to maintain a degree of comfort and dignity. Studies consistently support its effectiveness in improving quality of life for patients with advanced malignancies when administered under proper medical supervision.

How Diamorphine Is Administered for Severe Cancer Pain

Diamorphine can be delivered through several routes depending on the patient’s condition and clinical setting. The most common methods include subcutaneous injection, intravenous administration, and continuous subcutaneous infusion via a syringe driver. The syringe driver is especially valuable in palliative care, as it allows a steady, controlled delivery of medication over 24 hours without repeated injections, which is important for patients who can no longer swallow oral medications.

Key administration routes used in clinical practice include:

• Subcutaneous infusion — the most common route in hospice care, providing continuous pain relief.
• Intravenous injection — used in acute hospital settings for rapid onset of analgesia.
• Epidural or intrathecal delivery — reserved for complex cases requiring targeted spinal analgesia.

Because diamorphine is highly water-soluble compared to morphine, smaller volumes are required for injection, making it particularly practical for subcutaneous delivery. This pharmacological advantage is one reason it remains a preferred opioid in end-of-life care protocols across the United Kingdom.

Diamorphine in Oncology: Dosing, Safety, and Clinical Considerations

Diamorphine pain management in oncology requires individualized dosing based on the patient’s prior opioid exposure, renal function, age, and overall clinical status. Physicians typically begin with a conservative dose and titrate upward based on pain response and tolerability. Converting from oral morphine to subcutaneous diamorphine generally involves a dose reduction, as diamorphine is approximately three times more potent than oral morphine by equivalent weight.

The following table summarizes key clinical considerations for safe diamorphine use:

Common adverse effects include nausea, constipation, sedation, and respiratory depression. Naloxone should be available in clinical settings as a reversal agent in cases of overdose. Regular reassessment of pain and side effects is an essential component of responsible opioid stewardship in oncology. All prescribing and administration must comply with applicable controlled substance regulations and FDA guidelines where relevant.